The Michigan State University Molecular Discovery Grants (MSU-MDG) have been established between the Department of Pharmacology & Toxicology and MSU Drug Discovery to provide pilot funding for accelerating the discovery and development of chemical technologies with applications for human health, animal health and agricultural use (max $30,000; average: $10,000- 15,000). The primary aim of these funds is to advance projects toward extramural funding or to the creation or development of intellectual property and commercialization.

 

Specific goals include:

• Assisting investigators in advancing their programs in the early phases of the discovery process with long-term commercialization in mind.

• Supporting early activities (e.g. screening) not readily funded by other sources.

• Providing additional data to support extramural grant applications.

• Aiding in the discovery or development of intellectual property.

• Accelerating therapeutics or diagnostics discovery and development programs

 

For more information, please contact:

Joseph Nichols, PhD - MSU Drug Discovery - Project Manager 

Email:  nicho621@msu.edu

Molecular Discovery Grant Recipients

MDG Cycle	Investigator	Title
2/20	Jason Bazil, Ph.D.	The search for Novel Mitoprotectants Against Reperfusion Injury
	Bryan Copple, Ph.D.	Development of Machrphage Phenotypic Modulators as a Treatment for Liver Fibrosis
	Sean Crosson, Ph.D.	High Throughput Screening for Host-Directed Antimicrobials Against Intracellular Brucella
	Kathleen Gallo, Ph.D.	Mixed Lineage Kinase 3 Inhibitors for Glioblastoma
	Jian Hu, Ph.D.	Developing Cell-based High Throughput Screening to Identify Inhibitors Against Pathogenic Fungal ZIP Metal Transporters
	Kin Sing Stephen Lee, Ph.D.	Developing a sHE inhibitor with Improved Physicochemical Properties and CNS Penetration for Lupus
	Jeffrey MacKeigan, Ph.D	Small Molecule Inhibitors of ULK1
	Aaron Odom, Ph.D. /Jetze Tepe, Ph.D.	Exploration of in vivo Efficacy of Proteasome Inhibitors with Alternative Mechanisms
	Bryan Smith, Ph.D.	Marophage-selective Nanotherapy to Treat Breast Cancer
5/19	Robert Abramovitch, Ph.D.	Development of New Mycobacterium tuberculosis MmpL3 Inhibitors
	Bryan Copple, Ph.D.	Modulation of Macrophage Phenotype to Treat Liver Fibrosis and Cirrhosis
	Andrea Doseff, Ph.D. / Karen Liby, Ph.D.	Identifying Novel Strategies for the Treatment of Triple Negative Breast Cancer
	Erika Lisabeth, Ph.D.	Identification of Small Molecule Modulators of the Serum Response Factor
	Dohun Pyeon, Ph.D.	Developing Chemokine-based Novel Immunotherapies
	Christopher Waters, Ph.D.	Identifying Triclosan Analogs That Improve Synergy with Tobramycin to Eradicate Biofilms
9/17	Susan Conrad, Ph.D.	Identifying Novel Strategies for Endocrine-resistant Metastatic ER+ Breast Cancer
	Aaron Odom, Ph.D. / Jetze Tepe, Ph.D.	Exploration of Viability of Proteasome Inhibitors with Alternative Mechanisms
	Chrisopher Waters, Ph.D.	Identifying Compounds That Enhance Biocide Killing of Waters System Biofilms
	Stephanie Watts, Ph.D.	5-HT7 Receptor Drug Discovery for Cardiovascular Disease
	Yong-Hui Zheng, Ph.D.	High Throughput Screening of Novel Anti-HIV-1 Compounds
1/17	Robert Abramovitch Ph.D.	Medicinal Chemistry Optimizations of Lead Compounds That Inhibit M. tuberculosis Persistence and drug tolerance
	Andre Bachmann Ph.D.	Synthesis of Biological Evaluation of Phaseolotoxin-inspired ODC Inhibitors
	Jon Kaguni Ph.D.	Targeted Drug Discovery to Identify Inhibitors of Bacterial DNA Replication
	Hao-Min Kuo Ph.D.	Hyperphosphorylated tau Aggregation modulators as Candidates for Alzheimer's disease Therapeutics and Risk Factors
	Karen Liby, Ph.D.	Synthesis and Characterization of New Rexinoids
	Jetze Tepe, Ph.D.	Development of Drug-like TCH-165 Derivatives